

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A modified antibody of class IgG comprising a variable region from daclizumab and a heavy chain constant region, wherein at least amino acid residues 250 and 428 from the heavy chain constant region are different from the residues present in an unmodified class IgG antibody, wherein the FcRn binding affinity and/or serum half-life of said modified antibody is altered relative to that of the unmodified antibody, and wherein amino acid residues are numbered by the EU numbering system.

2. (currently amended) The modified antibody according to Claim 1, wherein said ~~unmodified class IgG antibody is selected from the group consisting of~~ heavy chain constant region is from daclizumab, ~~fontolizumab, visilizumab and M200.~~

3. (currently amended) An antibody comprising a variable region from daclizumab and a heavy chain constant region substantially identical to that of a naturally occurring class IgG antibody wherein at least amino acid residues 250 and 428 from the heavy chain constant region are different from that present in the naturally occurring class IgG antibody, wherein the FcRn binding affinity and/or serum half-life of said antibody is altered relative to the naturally occurring antibody, and wherein amino acid residues are numbered by the EU numbering system.

4. (currently amended) The antibody according to Claim 3 wherein said ~~naturally occurring class IgG antibody is selected from the group consisting of~~ heavy chain constant region is from daclizumab, ~~fontolizumab, visilizumab and M200.~~

5. (original) The antibody according to Claim 3, wherein:
(a) said amino acid residue 250 from the heavy chain constant region is glutamic acid or glutamine; or

(b) said amino acid residue 428 from the heavy chain constant region is phenylalanine or leucine.

6. (original) The antibody according to Claim 3, wherein said amino acid residue 250 from the heavy chain constant region is glutamine.

7. (original) The antibody according to Claim 3, wherein said amino acid residue 428 from the heavy chain constant region is leucine.

8. (original) The antibody according to Claim 3, wherein:
said amino acid residue 250 from the heavy chain constant region is glutamic acid and said amino acid residue 428 from the heavy chain constant region is phenylalanine;
said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is phenylalanine; or
said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is leucine.

9-12. (canceled)

13. (currently amended) A modified antibody of ~~claim~~ Claim 1 with an *in vivo* clearance at least about 1.3-fold lower than that of the corresponding unmodified class IgG antibody.

14-15. (cancel)

16. (original) A modified therapeutic antibody comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence selected from SEQ ID NOs: 119-128.

17-27. (canceled)

28. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 122.

29. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 127.

30. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 123.

31. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 128.

32. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 120.

33. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 125.

34. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 121.

35. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 126.

36. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 119.

37. (New) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 124.

38. (New) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG1.

39. (New) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG2M3.

40. (New) The modified antibody of Claim 3 wherein said class IgG antibody is a human IgG1.

41. (New) The modified antibody of Claim 3 wherein said class IgG antibody is a human IgG2M3.